Allergic Rhino-Conjunctivitis Market Report 2036: Outlook, Access And Commercial Opportunities Through 2036
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Allergic Rhino-Conjunctivitis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The global allergic rhinoconjunctivitis market is expected to maintain steady growth throughout the 2026-2036 forecast period. Market expansion will be supported by the condition's increasing prevalence, affecting more than 400 million people worldwide, alongside greater exposure to environmental allergens, urbanization, air pollution and longer pollen seasons associated with climate change. Increased investment in targeted biologics, allergen immunotherapy and other novel treatment approaches is also expected to reshape the allergic rhinoconjunctivitis treatment landscape.
Key Market Highlights
- The allergic rhinoconjunctivitis therapeutics market is projected to record a steady compound annual growth rate during 2026-2036. Growth drivers include rising IgE-mediated hypersensitivity, indoor and outdoor allergen exposure, improved diagnosis and the high prevalence of comorbid asthma, atopic dermatitis, sinusitis and ocular conjunctivitis. Approved allergen immunotherapies, including ORALAIR from Stallergenes Greer and ODACTRA from ALK-Abello, demonstrate the industry's shift from symptom control toward disease-modifying treatment. A significant unmet need remains for therapies that provide rapid, durable control of nasal and ocular symptoms while maintaining favorable safety profiles across pediatric and adult populations. Pipeline candidates such as Inmunotek's Phase III MM09-MG01 may increase competition and broaden future treatment options.
Comprehensive Allergic Rhinoconjunctivitis Market Report
The reportanalyzes seasonal and perennial allergic rhinoconjunctivitis across the seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. It includes historical and projected epidemiology, diagnosed prevalence, treated populations, subtype-specific cases and comorbidity-associated cases.
The analysis also examines diagnostic practices, prescribing trends, physician perspectives, market access, reimbursement, treatment patterns and emerging commercial opportunities. Country-level forecasts and therapy-specific market segmentation provide stakeholders with insights for product development, competitive benchmarking, portfolio planning and commercialization strategies.
Disease Diagnosis and Treatment Landscape
Allergic rhinoconjunctivitis is an IgE-mediated inflammatory disorder involving the nasal mucosa and conjunctiva following exposure to airborne allergens. Seasonal allergic rhinoconjunctivitis is commonly associated with grass, tree and weed pollens, while perennial disease is linked to year-round allergens such as house dust mites and pet dander.
Diagnosis is based on clinical history, symptom patterns, exposure history and confirmatory allergy testing. Skin prick testing is generally the preferred first-line method for detecting allergen-specific IgE sensitization, while serum-specific IgE testing may be used when skin testing is unavailable or contraindicated. Nasal cytology and nasal provocation testing can support the assessment of patients with suspected local allergic rhinitis.
Current management follows a stepwise approach that includes allergen avoidance, pharmacotherapy and allergen immunotherapy. Common treatments include intranasal corticosteroids, second-generation oral or nasal antihistamines, leukotriene receptor antagonists, mast cell stabilizers, nasal decongestants and anticholinergic therapies. The ARIA-EAACI 2024-2025 recommendations prioritize intranasal corticosteroids, intranasal antihistamines and fixed intranasal antihistamine-corticosteroid combinations according to disease severity and persistence.
Subcutaneous and sublingual allergen immunotherapy remain the principal disease-modifying approaches for patients with persistent symptoms despite pharmacotherapy. These options may be particularly important when reducing future asthma risk is a treatment priority, including in selected pediatric populations.
Allergic Rhinoconjunctivitis Epidemiology
Secondary analyses estimate that allergic rhinoconjunctivitis may affect approximately 30% of the population, with a substantial burden among children, adolescents and younger adults. An international study reported rhinoconjunctivitis symptoms in 13.3% of adolescents aged 13-14 years across 25 countries and 7.7% of children aged 6-7 years across 16 countries.
Longitudinal analyses in the United Kingdom indicate that allergic rhinoconjunctivitis affects approximately one in eight adults and one in 14 children, with prevalence increasing among adults. Regional differences across the seven major markets are influenced by genetic predisposition, pollen and dust mite exposure, smoking, air pollution, urban living and climate-related environmental changes.
Approved Allergic Rhinoconjunctivitis Therapies
ORALAIR, developed by Stallergenes Greer, is a sublingual allergen immunotherapy tablet containing extracts from five grass pollens. It is indicated for grass pollen-induced allergic rhinitis with or without conjunctivitis in patients aged five years and older. First authorized in Europe in 2009, ORALAIR received US Food and Drug Administration approval in April 2014, followed by an expanded pediatric indication in November 2018.
ODACTRA, developed by ALK-Abello, contains standardized extracts of Dermatophagoides farinae and Dermatophagoides pteronyssinus. The sublingual tablet is indicated for house dust mite-induced allergic rhinitis with or without conjunctivitis. Following earlier approvals in Japan, Europe and the United States, the FDA expanded ODACTRA's indication in February 2025 to include children aged five to 11 years.
Pipeline and Competitive Landscape
The allergic rhinoconjunctivitis pipeline includes candidates across Phase I-III clinical development. Inmunotek's MM09-MG01 is being evaluated in a Phase III randomized, placebo-controlled, multicenter study involving patients with mild to moderate asthma and allergic rhinitis or rhinoconjunctivitis caused by house dust mite hypersensitivity.
The report reviews clinical trial results, mechanisms of action, regulatory milestones, patents, licensing agreements, collaborations, strategic partnerships and anticipated development catalysts. Competitive intelligence incorporates SWOT analysis and market-entry considerations where sufficient data are available.
Market Outlook, Access and Commercial Opportunity
The United States accounted for a significant share of the seven-major-market allergic rhinoconjunctivitis market in 2025, supported by high diagnosed prevalence and treatment costs. This position is expected to continue as new products enter the market. Drug-uptake analysis assesses anticipated market penetration, class-level competition, regulatory and financial factors, clinical efficacy, safety, order of entry and the probability of commercial success.
Market access analysis covers country-specific healthcare systems, reimbursement policies and health technology assessments. The report also incorporates insights from more than 15 interviewed key opinion leaders across the seven major markets, selected from a broader network of over 50 clinical experts. Participating institutions include National Jewish Health, Charite - Universitatsmedizin Berlin, Hospital Clinic de Barcelona, Humanitas Research Hospital, Hopital Europeen Georges-Pompidou, Royal Brompton Hospital and Jikei University Hospital.
Strategic Value of the Report
- Eleven-year allergic rhinoconjunctivitis market forecast covering 2026-2036. Epidemiology and patient-population analysis across the seven major markets. Assessment of current treatment practices, prescription trends and unmet medical needs. Profiles of approved products and emerging allergic rhinoconjunctivitis therapies. Country-, class- and therapy-level market sizing and drug-uptake forecasts. Analysis of market access, reimbursement, competitive positioning and commercialization opportunities. Evaluation of collaborations, mergers and acquisitions, licensing activity and patent developments.
The allergic rhinoconjunctivitis market is positioned for continued evolution as rising disease prevalence, improved diagnostic awareness and expanding access to allergen immunotherapy increase demand. Advances in biologics, intranasal combination therapies and next-generation immunotherapy platforms may further address persistent gaps in symptom control, treatment adherence and long-term disease modification.
A selection of companies mentioned in this report includes, but is not limited to:
- Sanofi Regeneron Pharmaceuticals Eli Lilly Merck
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment